SynthesisNutrients2022
Cardiovascular Safety and Effectiveness of Bisphosphonates: From Intervention Trials to Real-Life Data.
Synthesis in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Effectiveness and Safety of Pharmacological Therapy for Osteoporosis in Frail Elderly Individuals: Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Protein lipidation in cardiovascular homeostasis, development, and disease.Clinical science (London, England : 1979) · 2026Review
- Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam study.Atherosclerosis plus · 2026Article
- Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004-2024).PloS one · 2026Article
- Longitudinal associations between medication use and phenotypic aging: insights from the Baltimore longitudinal study of aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Observational
- Real-world data from a national survey on management of CKD-associated osteoporosis among Italian nephrologists.Archives of osteoporosis · 2025Article
- A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database.Scientific reports · 2025Article
- Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.Journal of the National Cancer Institute · 2025Article
- Standard and advanced echocardiographic study of patients with Paget's disease of bone: Evidence of a pagetic heart disease?Journal of internal medicine · 2025Article
- Impact of multidimensional assessment on anti-fracture treatment decisions in patients with fragility hip fractures within a Fracture Liaison Service.BMC geriatrics · 2025Article
- Review
- Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors.JNCI cancer spectrum · 2025Article
- A practical approach for anabolic treatment of bone fragility with romosozumab.Journal of endocrinological investigation · 2024Review
- Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture.The Journal of clinical endocrinology and metabolism · 2024Article
- Insights and implications of sexual dimorphism in osteoporosis.Bone research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both osteoporosis with related fragility fractures and cardiovascular diseases are rapidly outspreading worldwide. Since they are often coexistent in elderly patients and may be related to possible common pathogenetic mechanisms, the possible reciprocal effects of drugs employed to treat these diseases have to be considered in clinical practice. Bisphosphonates, the agents most largely employed to decrease bone fragility, have been shown to be overall safe with respect to cardiovascular diseases and even capable of reducing cardiovascular morbidity in some settings, as mainly shown by real life studies. No randomized controlled trials with cardiovascular outcomes as primary endpoints are available. While contradictory results have emerged about a possible BSP-mediated reduction of overall mortality, it is undeniable that these drugs can be employed safely in patients with high fracture risk, since no increased mortality has ever been demonstrated. Although partial reassurance has emerged from meta-analysis assessing the risk of cardiac arrhythmias during bisphosphonates treatment, caution is warranted in administering this class of drugs to patients at risk for atrial fibrillation, possibly preferring other antiresorptives or anabolics, according to osteoporosis guidelines. This paper focuses on the complex relationship between bisphosphonates use and cardiovascular disease and possible co-management issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.